(Q33372340)

26 July 2017

1 reference

title

Temozolomide: a milestone in neuro-oncology and beyond? (English)

1 reference

26 July 2017

0 references

Nicole Mutter

1

1 reference

PubMed ID

16925485

26 July 2017

Roger Stupp

series ordinal

2

1 reference

26 July 2017

1 August 2006

1 reference

Expert Review of Anticancer Therapy

26 July 2017

1 reference

26 July 2017

6

1 reference

26 July 2017

8

1 reference

26 July 2017

1187-1204

1 reference

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

26 July 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

From triazines and triazenes to temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Is protracted low-dose temozolomide feasible in glioma patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

New chemotherapeutic agents for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A prospective study on glioblastoma in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide chemotherapy in recurrent oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II trial of temozolomide in patients with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Promises and controversies in the management of low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Role of temozolomide in pediatric brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II trial of temozolomide in children with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in paediatric high-grade glioma: a key for combination therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II study of temozolomide in advanced untreated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II study of temozolomide in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Optimal role of temozolomide in the treatment of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Clinical relevance of MGMT in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Changing paradigms--an update on the multidisciplinary management of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.8.1187

10.1586/14737140.6.8.1187

21 January 2018

Identifiers

DOI

1 reference

release_ruoq2ox3wrehhej2kl3wacaola

26 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ruoq2ox3wrehhej2kl3wacaola

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16925485

1 reference

PubMed ID

16925485